NPM1 and acute myeloid leukemia: As recommended previously [2], [3], the favorable outcome subgroup (n = 23) are those CN-AML patients who have the NPM1 gene mutation (NPM1mt) but do not have the internal tandem duplication in the FLT3 gene (FLT3ITD).